HER family receptor and ligand status in thymic carcinoma

Lung Cancer

Volumn 77, Issue 3, 2012, Pages 515-521

  Weissferdt, Annikka ^a   Lin, Heather ^a   Woods, Denise ^a   Tang, Ximing ^a   Fujimoto, Junya ^a   Wistuba, Ignacio I ^a   Moran, Cesar A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

EGFR; Fluorescence in situ hybridization; HER2; Immunohistochemistry; Mediastinum; Molecular biology; Thymic carcinoma

Indexed keywords

AMPHIREGULIN; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIREGULIN; TRANSFORMING GROWTH FACTOR ALPHA;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CENTROMERE; CLINICAL ARTICLE; ENZYME PHOSPHORYLATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DOSAGE; GENE FREQUENCY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MOLECULAR BIOLOGY; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; THYMUS CANCER;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; DNA COPY NUMBER VARIATIONS; EPIDERMAL GROWTH FACTOR; FEMALE; GENE DOSAGE; GLYCOPROTEINS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR; THYMOMA; THYMUS NEOPLASMS; TRANSFORMING GROWTH FACTOR ALPHA; YOUNG ADULT;

EID: 84865179235     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.05.108     Document Type: Article

References (43)

1. Tumours of the lung, pleura, thymus and heart 2004, 148-197. IARC Press, Lyon, France. W.D. Travis, E. Brambilla, H.K. Müller-Hermelink, C.C. Harris (Eds.).
2. Salomon D.S., Brandt R., Ciardiello F., Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995, 19:183-232.
3. Normanno N., Bianco C., De Luca A., Maiello M.R., Salomon D.S. Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer 2003, 10:1-21.
4. Ciardiello F., Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008, 358:1160-1174.
5. Duffy M.J., O'Donovan N., Crown J. Use of molecular markers for predicting therapy response in cancer patients. Cancer Treat Rev 2011, 37:151-159.
6. Varella-Garcia M. Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay. Diagn Pathol 2006, 15(1):19.
7. Massarelli E., Varella-Garcia M., Tang X., Xavier A.C., Ozburn N.C., Liu D.D., et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 2007, 13:2890-2896.
8. Yarden Y. The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001, 37(Suppl. 4):S3-S8.
9. Normanno N., Bianco C., Strizzi L., Mancino M., Maiello M.R., De Luca A., et al. The ErbB receptors and their ligands in cancer: an overview. Curr Drug Targets 2005, 6:243-257.
10. Olayioye M.A., Neve R.M., Lane H.A., Hynes N.E. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000, 19:3159-3167.
11. Normanno N., De Luca A., Bianco C., Strizzi L., Mancino M., Maiello M.R., et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006, 366:2-16.
12. Mendelsohn J., Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003, 21:2787-2799.
13. Holbro T., Civenni G., Hynes N.E. The ErbB receptors and their role in cancer progression. Exp Cell Res 2003, 284:99-110.
14. Hirsch F.R., Scagliotti G.V., Langer C.J., Varella-Garcia M., Franklin W.A. Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies. Lung Cancer 2003, 41(Suppl. 1):S29-S42.
15. Ionescu D.N., Sasatomi E., Cieply K., Nola M., Dacic S. Protein expression and gene amplification of epidermal growth factor receptor in thymomas. Cancer 2005, 103:630-636.
16. Girard N., Shen R., Guo T., Zakowski M.F., Heguy A., Riely G.J., et al. Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. Clin Cancer Res 2009, 15:6790-6799.
17. Suzuki E., Sasaki H., Kawano O., Endo K., Haneda H., Yukiue H., et al. Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors. Jpn J Clin Oncol 2006, 36:351-356.
18. Pan C.C., Chen P.C., Wang L.S., Lee J.Y., Chiang H. Expression of apoptosis-related markers and HER-2/neu in thymic epithelial tumours. Histopathology 2003, 43:165-172.
19. Meister M., Schirmacher P., Dienemann H., Mechtersheimer G., Schnabel P.A., Kern M.A., et al. Mutational status of the epidermal growth factor receptor (EGFR) gene in thymomas and thymic carcinomas. Cancer Lett 2007, 248:186-191.
20. Aisner S.C., Dahlberg S., Hameed M.R., Ettinger D.S., Schiller J.H., Johnson D.H., et al. Epidermal growth factor receptor, C-kit, and Her2/neu immunostaining in advanced or recurrent TENs staged according to the 2004 World Health Organization in patients treated with octreotide and prednisone: an Eastern Cooperative Oncology Group study. J Thorac Oncol 2010, 5:885-892.
21. Yoh K., Nishiwaki Y., Ishii G., Goto K., Kubota K., Ohmatsu H., et al. Mutational status of EGFR and KIT in thymoma and thymic carcinoma. Lung Cancer 2008, 62:316-320.
22. Hayashi Y., Ishii N., Obayashi C., Jinnai K., Hanioka K., Imai Y., et al. Thymoma: tumour type related to expression of epidermal growth factor (EGF), EGF-receptor, p53, v-erb B and ras p21. Virchows Arch 1995, 426:43-50.
23. Yamaguchi H., Soda H., Kitazaki T., Tsukamoto K., Hayashi T., Kohno S. Thymic carcinoma with epidermal growth factor receptor gene mutations. Lung Cancer 2006, 52:261-262.
24. Meert A.P., Martin B., Delmotte P., Berghmans T., Lafitte J.J., Mascaux C., et al. The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis. Eur Respir J 2002, 20:975-981.
25. Hirsch F.R., Varella-Garcia M., Franklin W.A., Veve R., Chen L., Helfrich B., et al. Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas. Br J Cancer 2002, 86:1449-1456.
26. Liu L., Shao X., Gao W., Bai J., Wang R., Huang P., et al. The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data. J Thorac Oncol 2010, 5:1922-1932.
27. Takikita M., Xie R., Chung J.Y., Cho H., Ylaya K., Hong S.M., et al. Membranous expression of Her3 is associated with a decreased survival in head and neck squamous cell carcinoma. J Transl Med 2011, 9:126.
28. Begnami M.D., Fukuda E., Fregnani J.H., Nonogaki S., Montagnini A.L., da Costa W.L., et al. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. J Clin Oncol 2011, 29:3030-3036.
29. Kim S.J., Rabbani Z.N., Dong F., Vollmer R.T., Schreiber E.G., Dewhirst M.W., et al. Phosphorylated epidermal growth factor receptor and cyclooxygenase-2 expression in localized non-small cell lung cancer. Med Oncol 2010, 27:91-97.
30. Kondo N., Tsukuda M., Taguchi T., Nakazaki K., Sakakibara A., Takahashi H., et al. Gene status of head and neck squamous cell carcinoma cell lines and cetuximab-mediated biological activities. Cancer Sci 2011, 102:1717-1723.
31. Schreiber A.B., Winkler M.E., Derynck R. Transforming growth factor-alpha: a more potent angiogenic mediator than epidermal growth factor. Science 1986, 232:1250-1253.
32. Busser B., Sancey L., Brambilla E., Coll J.L., Hrubin A. The multiple roles of amphiregulin in human cancer. Biochim Biophys Acta 2011, 1816:119-131.
33. Amann J., Kalyankrishna S., Massion P.P., Ohm J.E., Girard L., Shigematsu A., et al. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res 2005, 65:226-235.
34. Ishikawa N., Daigo Y., Takano A., Taniwaki M., Kato T., Hayama S., et al. Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. Cancer Res 2005, 65:9176-9184.
35. Fontanini G., De Laurentiis M., Vignati S., Chinè S., Lucchi M., Silvestri V., et al. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin Cancer Res 1998, 4:241-249.
36. Addison C.L., Ding K., Zhao H., Le Maitre A., Goss G.D., Seymour L., et al. Plasma transforming growth factor alpha and amphiregulin protein levels in NCIC Clinical Trials Group BR.21. J Clin Oncol 2010, 28:5247-5256.
37. Zhang J., Iwanaga K., Choi K.C., Wislez M., Raso M.G., Wei W., et al. Intratumoral epiregulin is a marker of advanced disease in non-small cell lung cancer patients and confers invasive properties on EGFR-mutant cells. Cancer Prev Res (Phila) 2008, 1:201-207.
38. Castillo J., Erroba E., Perugorría M.J., Santamaria M., Lee D.C., Prieto J., et al. Amphiregulin contributes to the transformed phenotype of human hepatocellular carcinoma cells. Cancer Res 2006, 66:6129-6138.
39. Hurbin A., Dubrez L., Coll J.L., Favrot M.C. Inhibition of apoptosis by amphiregulin via an insulin-like growth factor-1 receptor-dependent pathway in non-small cell lung cancer cell lines. J Biol Chem 2002, 277:49127-49133.
40. Kenny P.A., Bissell M.J. Targeting TACE-dependent EGFR ligand shedding in breast cancer. J Clin Invest 2007, 117:337-345.
41. Normanno N., Selvam M.P., Bianco C., Damiano V., de Angelis E., Grassi M., et al. Amphiregulin anti-sense oligodeoxynucleotides inhibit growth and transformation of a human colon carcinoma cell line. Int J Cancer 1995, 62:762-766.
42. Ströbel P., Bargou R., Wolff A., Spitzer D., Manegold C., Dimitrakopoulou-Strauss A., et al. Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience. Br J Cancer 2010, 103:196-200.
43. Bisagni G., Rossi G., Cavazza A., Sartori G., Gardini G., Boni C. Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma. J Thorac Oncol 2009, 4:773-775.